Lorraine Provencher, MD
Ophthalmology · Omaha, NENPI 1174935910
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $156,478 of the $220,182 with a category attached, or 71.1%. 27 manufacturers reported payments, led by AbbVie at 38.1% of the total. Among ophthalmology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $756.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- Alcon$51K
- Microsurgical Technology, Inc.$28K
- Glaukos Corporation$28K
- Alcon Research LLC$10K
- NEW World Medical,inc.$8K
- plus $11K from 21 others
Across 29 payments — averaging $4390.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$46K
- AbbVie$46K
- Glaukos Corporation$32K
- Sight Sciences, Inc.$3K
What the payments were for
- Consulting fees$156,47871%
- Speaking & faculty fees$50,02823%
- Travel & lodging$4,3442%
- Food & beverage$9,3324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $83,792 |
| Alcon | 65 | $51,282 |
| Microsurgical Technology, Inc. | 2 | $28,250 |
| Glaukos Corporation | 39 | $27,831 |
| Alcon Research LLC | 4 | $10,248 |
| NEW World Medical,inc. | 14 | $7,632 |
| Thea Pharma Inc. | 2 | $3,038 |
| Ivantis, Inc | 8 | $2,955 |
| Rxsight Inc | 7 | $2,375 |
| Bausch & Lomb Americas Inc. | 11 | $1,811 |
| Harrow Eye, LLC | 3 | $212 |
| Aerie Pharmaceuticals, Inc. | 3 | $147 |
| Ocular Therapeutix, Inc. | 3 | $142 |
| Tarsus Pharmaceuticals, Inc. | 4 | $127 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $33 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Novartis | 2 | $30 |
| Biotissue Holdings Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Dompe US, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Alimera Sciences, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$49,206
- Hydrus Microstent$42,326
- DURYSTA$25,381
- Rocklatan$11,306
- Voyager DSLT$9,000
- ILUX$5,700
- Systane$5,700
- LenSx$5,700
- iDose$5,700
- Kahook Dual Blade$4,800
- Clearpath$4,800
- Ahmed Glaucoma Valve$4,800
- Streamline$4,800
- LUMIGAN$4,137
- Via360$2,400
- Travoprost Intraocular Implant - iDose$2,250
- RXSIGHT CONTACT LENS$2,184
- RXSIGHT INJECTOR CARTRIDGE$2,184
- RXSIGHT INJECTOR HANDPIECE$2,184
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,184
How this compares
$220,182 in reported general payments places this provider in the 95th percentile of 105 ophthalmology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 13 | $7,981 |
| ProlensaBromfenac Sodium | 12 | $5,934 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,903 |
| Prednisolone Acetate | 180 | $5,116 |
| MoxifloxacinMoxifloxacin Hcl | 152 | $3,895 |
| Difluprednate | 36 | $3,103 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 83 | $1,137 |
| Latanoprost | 131 | $1,102 |
| Brimonidine Tartrate | 43 | $757 |
| Atropine Sulfate | 13 | $552 |
| Timolol Maleate | 57 | $505 |
| Dorzolamide Hcl | 31 | $398 |
| Acetazolamide ErAcetazolamide | 12 | $388 |
| Ketorolac Tromethamine | 25 | $357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $147 | $13,88526 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $33 | $5,93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 ophthalmology providers in Nebraska.
Other ophthalmology in Omaha
- Brandon BaartmanOmaha$226K
- Ronald KruegerOmaha$224K
- Lance KuglerOmaha$41K
- Rao ChunduryOmaha$14K
- Shane HavensOmaha$6K
- Brandon MenkeOmaha$6K
- Sao LiuOmaha$5K
- Michael HalstedOmaha$4K
- Thomas HejkalOmaha$4K
- Sao LiuOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.